Bispecific T-Cell Engagers Development Trends

This technical report outlines the trends in the development of bispecific T-cell engagers (BiTEs) post-2014, emphasizing the regulatory milestones that have shaped the landscape. It describes the significant impact of the FDA's accelerated approval of blinatumomab in 2014, which marked a turning point for BiTEs, validating their clinical viability and establishing a pathway for future approvals. The report details the current approval landscape, noting that while hematologic malignancies dominate, there are emerging solid tumor applications, particularly in small cell lung cancer. The report further discusses the concentration of BiTE activity in multiple myeloma, attributing it to favorable target density and measurable disease responses. It highlights the strategic shift in the myeloma landscape from BCMA-targeting to exploring additional targets like GPRC5D due to market saturation. The report also touches on the challenges faced in solid tumors and the nascent development of BiTEs in immunology, indicating a cautious but expanding interest in non-oncology applications.